Table II.
Trend in anthropometric and hemodynamic parameters during the trial in the different treatment groups
| Parameter | Placebo arm (n = 30; F = 14, M = 16) | Low-dose arm (n = 30; F = 15, M = 15) | High-dose arm (n = 30; F = 14, M = 16) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week-6 follow-up | Week-12 follow-up | Baseline | Week-6 follow-up | Week-12 follow-up | Baseline | Week-6 follow-up | Week-12 follow-up | |
| WC [cm] | 88.2 ±4.2 | 87.1 ±3.9 | 87.2 ±4.0 | 89.3 ±4.4 | 88.2 ±4.0 | 87.1 ±3.8 | 87.4 ±3.8 | 85.8 ±3.4 | 85.2 ±3.3 |
| BMI [kg/m2] | 27.0 ±1.2 | 26.8 ±1.1 | 26.7 ±1.3 | 26.8 ±1.3 | 26.7 ±1.2 | 26.5 ±1.3 | 26.8 ±1.4 | 26.7 ±1.3 | 26.0 ±1.1 |
| BF (%) | 32 ±3 | 31 ±4 | 31 ±2 | 33 ±4 | 32 ±4 | 32 ±4 | 34 ±4 | 33 ±4 | 31 ±3* |
| SBP [mm Hg] | 128 ±4 | 129 ±3 | 128 ±5 | 129 ±4 | 126 ±3 | 127 ±4 | 125 ±4 | 124 ±5 | 123 ±5 |
| DBP [mm Hg] | 82 ±2 | 83 ±3 | 83 ±2 | 82 ±2 | 85 ±3 | 84 ±2 | 84 ±2 | 83 ±3 | 83 ±3 |
| Endothelial reactivity (%) | 1.38 ±0.21 | 1.31 ±0.19 | 1.35 ±0.20 | 1.33 ±0.24 | 1.37 ±0.21 | 1.39 ±0.19 | 1.36 ±0.17 | 1.39 ±0.22 | 1.44 ±0.15* |
*
P < 0.05 vs. baseline. WC – waist circumference, BMI – body mass index, BF – body fat, SBP – systolic blood pressure, DBP – diastolic blood pressure.